IHL-42X
Obstructive Sleep Apnea (OSA)
Key Facts
Indication
Obstructive Sleep Apnea (OSA)
Phase
Phase 2/3
Status
Active - Pivotal trial ongoing
Company
About Incannex Healthcare
Incannex Healthcare is a clinical-stage biotech focused on developing proprietary cannabinoid and psychedelic-based therapies for conditions with high unmet need, including sleep apnea and anxiety disorders. The company has progressed its lead asset, IHL-42X for OSA, into pivotal Phase 2/3 trials and is advancing a psilocybin program for GAD. Its strategy centers on securing intellectual property around novel formulations and treatment protocols to build a valuable clinical pipeline, funded through its dual listing on the ASX and NASDAQ.
View full company profileTherapeutic Areas
Other Obstructive Sleep Apnea (OSA) Drugs
| Drug | Company | Phase |
|---|---|---|
| SCI-110 | SciSparc | Preclinical |
| Inspire 4.0 / Next-Gen System | Inspire Medical Systems | Development |
| DeltaWave CPAP Nasal Pillow System | Remsleep | Commercial |
| AD109 | Apnimed | Phase 3 |
| Sleep Apnea Biomarker Services | The Siesta Group | Service Offering |
| Injectable Neurostimulation System | Invicta Medical | Proof-of-Concept |